Ben Izar's lab is a pioneer in combining single cell techniques, genome-editing, and systems biology to explore the cancer field’s most pressing problems.
Including BRCA1 testing with prenatal carrier screening could identify people at risk of breast, ovarian, and pancreatic cancer at a time when cancer screening could save their lives.
A study from Columbia researchers suggests that changing a single letter in the DNA code of selected genes in T cells may supercharge cell therapies against cancer.
Columbia researchers have identified cells that give rise to Barrett’s esophagus, a precursor to esophageal cancer, the fastest-growing cancer in the United States.
Riders, sponsors, volunteers, and friends joined forces for Velocity, Columbia's Ride to End Cancer, in support of the Herbert Irving Comprehensive Cancer Center.
Cancer immunotherapy drugs only work for a minority of patients, but a generic drug now used to increase blood flow may be able to improve those odds, a study by Columbia University Medical Center researchers suggests.
Immunotherapy expert Pawel Muranski speaks about the new CAR-T therapy for leukemia and his work to bring T cell therapies to patients with a wide range of cancers.
Velocity is a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUIMC. Columbia riders share why they joined the cause.